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Inhibitory action of certain cyclophosphate derivatives 
of cAMP on CAMP-dependent protein kinases 
Rene J W DE WIT, Doeke HEKSTRA, Bernd JASTORFF, Wojciech J STEC, Janina BARANIAK, Roe1 VAN DRIEL 
and Petei J M VAN HAASTERT 
Cell Biology and Moi phogenesis Unit, Zoological Laboratory, University of Leiden 
(Received January 271March 26, 1984) - EJB 84 0100 
A series CAMP derivatives with modifications in the adenine, ribose and cyclophosphate moiety were screened 
for their binding affinity for ;the two types of CAMP-binding sites in mammalian protein kinase type I. In addition, 
the activation of the kinase by these analogs was monitored. The binding data indicate that CAMP is bound to both 
sites in a comparable manner : the adenine appears to have no hydrogen-bond interactions with the binding sites, 
whereas the ribose may be bound by three hydrogen bonds involving the 2’,  3’ and 5’ positions of CAMP. The 
binding data are not conclusive about the nature of the interaction with the exocyclic oxygen atoms on phosphorus, 
though a charge interaction seems to be absent. The cAMP molecule seems to be bound in the syn conformation. 
The results of activation experiments show that modifications in the adenine and ribose moiety do not affect the 
maximal activation level, while alteration of the two exocyclic oxygen atoms may result in a reduced maximal 
activation level and in one case, (RJ-adenosine 3’, 5’-monophosphorothioate [R,-CAMPS], in total absence of 
activation even at concentrations at which the analog saturates both binding sites. Since occupancy of the CAMP- 
binding sites by this derivative apparently did not lead to activation of the enzyme, we examined whether this 
compound could antagonize: the activation by CAMP. Indeed (RJ-CAMPS was found to inhibit CAMP stimulated 
kinase activity at concentrations compatible to its binding affinity. Also with mammalian protein kinase type I1 
(R,)-CAMPS showed antagonistic activity, while with a CAMP-dependent protein kinase from Dictyostelium 
discoideum partial agonistic activity was observed. 
Previously a mechanism for activation of protein kinase type I was proposed involving a charge interaction 
between the equatorial exocyclic oxygen atom and the binding site [De Wit et al. (1982) Eur. J.  Biochem. 122, 
95 - 991. This was based on measurements with impure preparations of (R,)-CAMPS and the R, and S, isomers 
adenosine 3’, 5’-monophosphodimethylamidate, cAMPN(CH,), . The present work using highly purified 
compounds suggests the absence of a charge interaction, since the uncharged analog (S,)-cAMPN(CH,), activates 
the kinase effectively. The data seem compatible with an activation model involving the formation of a covalent 
bond with phosphorus in both CAMP binding sites. 
It is well established that mammalian CAMP-dependent 
protein kinases are activated by a CAMP-induced release of 
free (active) catalytic subunits from a tetrameric holoenzyme 
[l]. The holoenzyme consists of two catalytic and two 
regulatory subunits and each regulatory subunit binds two 
molecules of cAMP to distinct sites. In the cellular slime mold 
Dictyosteliurn discoideum a CAMP-dependent protein kinase 
has been reported which showed different properties. The 
holoenzyme apparently consists of more than four subunits, 
the 40-kDa regulatory subunit contains one type of CAMP- 
binding site and the catalytic subunits often form large 
aggregates [2 - 51. Mammalian CAMP-dependent protein ki- 
nases have been studied using over 200 derivatives of CAMP. 
Recently several derivatives were observed to bind with clearly 
distinct affinity to the two types of binding sites, suggesting a 
difference in structure of the binding sites [6 -91. The use of 
these selective analogs led to the conclusion that both sites are 
involved in the activation of the kinase [I0 - 121. 
Ahbrwintiuns. CAMPS, adenosine 3‘,5’+monophosphorothioate; 
cAMPN(CH,),, adenosine 3’,5’-monopbosphodimethylamidate; 
HPLC, high-performance liquid chromatography. 
~~ ~ 
Trioid name. Kemptide, Leu-Arg-Arg-,Ala-Ser-Leu-Gly. 
Enzyme. CAMP-dependent protein kinase (EC 2.7.1.37). 
Our approach for studying the binding sites and activation 
mechanism is different : a selected series of 16 CAMP analogs is 
used, of which each one is modified in order to probe one 
possibly essential interaction with the binding site [I 3,141. 
Thus a scheme of the interactions of cAMP with its binding 
proteins could be obtained [15]. 
Recently, one of the CAMP binding sites (‘stable’, B, or 1) 
of protein kinase type I was mapped using this approach [16]. 
It was observed that one compound, (RJ-CAMPS, was 
defective in stimulating kinase activity, though binding ex- 
periments revealed that this compound bound competitively 
with CAMP. At concentrations of (R,)-CAMPS saturating the 
‘stable’ site, only a slight activation was observed. A similar 
observation was reported for type I1 protein kinase [17]. In 
addition, binding studies revealed that all derivatives had a 
lower affinity for the ‘stable’ binding site of the holoenzyme 
than of the free regulatory subunit, except (RJ-CAMPS, (RJ -  
cAMPN(CH,), and (S,)-cAMPN(CH,), . It was concluded 
that these compounds failed to establish a charge interaction 
with the ‘stable’ binding site. In the case of CAMP this leads to 
an increased binding affinity and activation by inducing a 
conformational change in the regulatory subunits and sub- 
sequent dissociation of the holoenzyme. In other words : there 
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is no coupling between binding of these cAMP derivatives and 
activation of the enzyme. 
In the present work the relation between binding of CAMP 
derivatives and activation is elaborated to the 'labile' site (site 
A or 2). Since the previously used preparations [16J of (Rp)- 
CAMPS and (R,)-cAMPN(CH,), contained 2 - 6 4 of the 
respective S, isomers and up to 10% of CAMP, and (Sp)- 
cAMPN(CH,), was found to be degraded to a large extent, 
these preparations were repurified and now contained less than 
0.1 "4 contaminations. As a result the new data for binding and 
activation readjust the data presented earlier. Furthermore it is 
demonstrated that analogs defective in astivating protein 
kinase type I are able to antagonize CAMP-induced activation. 
The agonistic and antagonistic potencies of the four de- 
rivatives with modified exocyclic oxygen atoms were also 
investigated in two other types of protein kinases: type I1 from 




[g-32P]ATP was purchased from New England Nuclear 
(Dreieich, FRG) and [2,8-,H]cAMP from Amersham Inter- 
national (Buckinghamshire, UK). CAMP, ATP, cGMP, cIMP, 
6-chloropurine-ribose 3',5'-monophosphate, S-bromoadeno- 
sine 3',5'-monophosphate and 2'-deoxyadenosine 3',5'-mono- 
phosphate were obtained from Boehringer (Mannheim, FRG). 
Adenosine N-oxide 3'3'-monophosphate, 3'-amino-3'-deoxy- 
adenosine 3',5'-monophosphate, 5'-amino-5'-deoxyadenosine 
3',5'-monophosphate, the S, and R, isomers of adenosine 3'3 ' -  
monophosphorothioate, benzimidazole-ribose 3',5'-mono- 
phosphate and purine-ribose 3',5'-monophosphate were syn- 
thesized as published previously [I8 -221. The synthesis of the 
S, and R, isomers of adenosine 3',5'-monophosphodimethyl- 
amidate will be published elsewhere. Dr R. Hanze (Upjohns) 
kindly supplied 7-deazaadenosine 3',5'-monophosphate and 
Dr J. Miller (SRI International Life Sciences Division, Menlo 
Park, CA, USA) supplied 2-phenyladenosine 3',5'-monophos- 
phate. Sephacryl S-300 was purchased from Pharmacia 
(Uppsala, Sweden), kemptide (Leu-Arg-Arg-Ala-Ser-Leu- 
Gly) was from Sigma (St Louis, MO, USA). The analogues 
(R,)-CAMPS, (S,)-CAMPS, (R,)-cAMPN(CH,), and ( S J -  
AMPN(CH,), were checked for the absence of cAMP or 
other impurities by high-performance liquid chromatography 
(HPLC) and, if necessary, purified by HPLC. 
En-y 7 mes 
CAMP-dependent protein kinase type I from rabbit ske- 
letal muscle was isolated and purified to homogeneity as in [23] 
and [24]; kinase type I1 from rabbit skeletal muscle was 
obtained from Sigma. CAMP-dependent protein kinase holo- 
enzyme from Dictyosteliuin discoideum strain AX-2 was 
isolated from aggregative cells as described in [4]. After 
homogenization, the cytosolic fraction was chromatographed 
over Sephacryl S-300 and fractions containing most of the 
CAM P-dependent kinase activity were pooled. 
Binding assay 
Ligand bound to CAMP-dependent protein kinase was 
determined by a filtration assay using cellulose-nitrate filters 
(Sartorius, Gottingen, FRG). The concentrations of [,HI 
cAMP (10000cpm/pmol) were 30nM. 100nM and 300nM 
and in the presence of 0.2 mM ATP tenfold higher. The 
incubation was at 25 "C for I h in 25 mM 4-morpholine- 
ethanesulfonic acid (Mes) pH 6.9, 4 mM magnesium acetate, 
0.125 mM EGTA, 1 mg/ml bovine serum albumin and various 
concentrations of competing cAMP derivative. After cooling 
on ice for 10 min, 50 p1 of each 100-p1 sample was filtered 
directly for determination of binding to both sites, while 20 pM 
unlabeled cAMP was added to the remaining 50 pl. At 0 "C in 
the presence of excess unlabeled cAMP the two types of 
binding sites release bound [,HICAMP at different rates. For 
the 'stable' site a rate constant of 0.029 h-.' was obtained 
(0.23 h-' in the presence of 0.2 mM ATP) and for the 'labile' 
site 0.49 h- l  (3.3 h- '  with ATP present). Both binding types 
contributqd 50+5% of the total binding. After 7 h of 
dissociation at 0 "C (or 1 h in case 0.2 mM ATP was present) 
the samples were filtered, yielding 82 A of the original binding 
to the slowly dissociating 'stable' (B or 1) site and about 3.0% 
of the original binding to the other site. After correction for the 
loss in binding to the 'stable' site this value was substrated from 
the total binding, yielding binding to the 'labile' site. The data 
were plotted according to Dixon [25]; all analogs were competi- 
tive inhibitors of [3H]cAMP binding. 
Kinase assay 
Protein kinase activity was determined in 60-pI samples 
containing 50 mM Mes pH 6.5, 5 mM magnesium chloride, 
0.5 mM EGTA, 10 mM sodium fluoride, 2.5 mM dithio- 
threitol, 20 pM kemptide. 0.2 mM Pp3'P]ATP (50 cpm/pmol), 
1 mg/ml bovine serum albumin, about 0.5 nM enzyme and 
various concentrations of cyclic nucleotides. The reaction was 
started by addition of 30 pl enzyme solution and terminated 
after a 10-min incubation at 30 "C by addition of 600 pl of a 
507; slurry of Dowex 1 x 2  in 307; acetic acid. After equilibra- 
tion for 1 h, samples were centrifuged for 2 min at 10000 xg. 
Radioactivity (in 175 1-11 supernatant) was determined by 
measuring Cerenkov irradiation. 
Standardization 
cAMP binding to the holoenzyme is strongly dependent 
on, for example, enzyme concentration and salt concentration 
[26 -281. In order to compare results in different systems, the 
following standardization is used [29] : 
K(cAMP) 
K(derivative) ' 
6AG= -RTln -  
K is either K, (the inhibition constant derived from Dixon 
plots) or K, (the concentration of analog yielding half- 
maximal activation of kinase activity). The increment in 
binding energy (6AG) is 5.70 or 5.80 kJ mol-I for a tenfold 
increase in K value measured at 25 "C or 30 "C, respectively. 
RESULTS 
Binding to the 'stable' and 'labile' sites 
As is shown in Table 1, the binding data of most of the 
derivatives were very similar for the two distinct sites. It thus 
appears that the interactions between cAMP and both bind- 
ing sites are basically identical: no hydrogen bonding with the 
adenine moiety, but still a similar specificity for derivatives 
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Table 1. Binding and acfiaation by C A M P  derivativesfor protein kinase type I 
The potencies of CAMP derivatives as activators of protein kinase type I (K,  values) were related to that of CAMP and transformed into the free 
enthalpy scale as described under Experimental Procedures. The maximal activation levels of the analogs were also related to that of CAMP, and 
K, values were related to the K ,  values of CAMP (53 nM for the ‘stable’ site; 25 nM for the ‘labile’ site) and transformed to (SAG values. The 
increase in 6dC for both binding sites as a result (of the presence of 0.2 mM ATP is shown in columns 2 and 4. The analog (RJ-cAMPN(CH,), did 
not reach the level of maximal activation; thercfore minimum estimates of this level and of the 6dG value are shown. All determinations were 
done at least in triplicate. The standard deviation for binding data of the ‘stable’ site (CAMP, n= 10) is about 1 kJ mol-’; of the ‘labile’ site 
(CAMP, n=10) about 1.5 kJ mol-’ and for activation (CAMP, n = 5 )  about 3 kJ mol-’ 
Analog Binding increment, 6AG Activation Level of 
~~ inci ement, maximal 
‘stable’ site ‘labile’ site bAG activation 
~- ____ 
- ~ ~ _ _ _ _  ~ ~ ~ ~ _ _ _ _ _ _ _ _ ~  ~ 




Adenosine 3‘,5‘-monophosphate 0 f 5 . 8  0 + 8.1 0 1 .0 
6-Chloropurine-ribose 3‘,5‘-monophosphate - 0.1 f 6 . 8  3.6 + 7.1 1 .0 1.1 
Benzimidazole-ribose 3’,5’-monophosphate 5.2 f 7 . 1  6.7 + 6.1 6.1 1.1 
Inosine 3’,5’-monophosphate 8.8 + 6.2 2.2 + 10.2 8.6 I .0 
Guanosine 3‘,5‘-monophosphate 12.7 + 6.2 11.9 + 6.6 12.5 1 .0 
Adenosine N-oxide 3‘,5‘-monophosphate 6.3 + 6.4 5.6 + 7.1 6.0 0.95 
7-Deazaadenosine 3‘,5’-monophosphate 4.0 f 6 . 0  - 0.3 + 6.1 0.6 0.95 
Purine-ri bose 3 ’, 5 ’-mon ophosphate 3.7 +5.1 2.0 + 6.0 3.5 0.9 
2-Phenyladenosine 3’,5’-monophosphate 8.0 +6.3 20.3 + 8.1 7.4 0.95 
8-Bromoadenosine 3’,5’-monophosphate - 0.8 +5.2 - 1.4 + 6.2 - 1.1 0.9 
2’-Deoxyadenosine 3’,5’-monophosphdte 20.2 +6.1 20.2 + 6.0 17.9 1.15 
3‘-Amino-3’-deoxyadenosine 3’,5’-monophosphate 17.1 + 7.1 18.1 + 5.6 17.3 0.9 
5’-Amino-5’-deoxyadenosine-3’,5’-monophosphate 17.2 +6.4 16.8 + 6.6 17.0 0.95 
< 0.03 
Adenosine 3’,5’-monophospho-dimethylamid,.1te (S,) 1 I .0 +6.5 12.6 + 8.0 10.8 0.75 
Adenosine 3’,5’-monophospho-dimethylamidate (R,) 21.3 +1.5 24.0 + 5.1 2 21.9 2 0.4 
Adenosine 3’,5’-monophosphorothioate (S,) 9.2 +4.6 9.4 + 8.5 8.8 1 .0 
Adenosine 3‘,5‘-monophosphorothioate (R,) 15.2 -0.2 15.9 + 0.9 - 
modified in this region. This suggests that, whatever is the 
basis for recognition of the adenine, similar molecular intcr- 
actions are responsible for recognition and binding of the base 
moiety to both sites. A minor site selectivity as observed before 
[6 - 121 was also found in our experiments. This could be due 
to a non-identical amino acid composition at the two sites. In 
addition, the CAMP molecule seems to be bound to both sites 
in the syn conformation as is suggested by the high affinity of 
the 8-bromo derivative of CAMP. This derivative is pre- 
ferentially in the syn conformation, while cAMP shows no 
preference for this conformation. The: ribose seems to be 
bound by at least three hydrogen bonds involving the 2’- 
hydroxyl and 3’ and 5’ oxygen atoms. The nature of the 
interaction(s) between the exocyclic oxygen atoms on phos- 
phorous and the binding sites is less obvious. The presence of a 
charge interaction is unlikely since (S,)-cAMPN(CH,), ,which 
is uncharged, binds relatively well, when compared to two 
derivatives in which the charge is mainly present in either the 
axial or the equatorial position, (R,)-CAMPS and (SJ-CAMPS 
respectively (Fig. 1). Remaining possibilities are hydrogen 
bonds, dipole interactions or formation of a pcntacovalent 
phosphorus atom, in which a covalent bond between the 
binding site and phosphorus induces formation of a trigonal 
bipyramid around this atom. 
Activation in relation to binding 
The majority of the analogs was able to stimulate the kinase 
activity to the same extent as CAMP (Table 1). Clearly, 
modifications of the adenine and ribose moiety, including the 
endocyclic oxygen atoms of the cyclophosphatc ring, do not 
affect the activating potency of CAMP. However, the four 
analogs that are modified in the two cxocyclic oxygen atoms 
arc important tools in the elucidation of the activation 
mechanism, since two of these show a clearly impaired 
maximal activation level, while one did not elicit any detectable 
activation. Thus, as proposed before [16], the phosphate 
region is not only involved in binding of CAMP, but also in the 
process of activation, i .  e. induced dissociation of holoenzyme. 
This is also observed when binding data of these compounds 
obtained in the presence of ATP are compared to those 
obtained without ATP. As ATP stabilizes the holoenzyme, 
which has a lower affinity for CAMP than free regulatory 
subunits [30], the binding affinity should be lower in the 
presence of ATP. This was indeed found for the majority of thc 
derivatives including cAMP and for both binding sites, but not 
for (R,)-CAMPS and to a minor extent for (RJ-cAMPN- 
(CH,), (Table 1). It is a remarkable observation that these 
derivatives also show a reduced level of maximal activation 
[though for (R,)-cAMPN(CH,), this is less certain, since the 
maximal level was not reached at the highest concentration of 
this compound that could be achieved]. (R,)-CAMPS did not 
stimulate the kinase activity to a detectable extent (< 3 % of 
CAMP), while (S,)-cAMPN(CH,), activated the kinase to 
75% of the level of cAMP (Fig. 2). Apparently a correlation 
exists between the extent of lowering of the binding affinity for 
both sites due to ATP and the maximal activation level 





Sp- CAMPS Rp-cAMPS 
OH OH 
Sp- cAMPNCH,), Rp-cAMPNCH3), 
Fig. 1 .  Structures and names of the analogs with modijied exocyclic 
o-xygen atoms. Ad =adenine 
lo9 1c7 I$ lo3 
[analog], M 
Fig. 2. Dose-response curresfor mammalian kinase type I activation by 
cAMP and dericatives with modified exocyclic oxygen atoms. The 
kinase activity is expressed as a percentage of the maximal activation 
by cAMP (100% corresponds to about 30 pmol 32P incorporated in 
kemptideimin). Symbols: (0) CAMP; (0) (S,)-CAMPS; (A) (&)- 
CAMPS : (A) (S,)-cAMPN(CH,), and (0) (R,)-cAMPN(CH,), 
of cAMP for both binding sites upon dissociation of holoen- 
zyme is the driving force for the dissociation of holoenzyme, 
according to a closed thermodynamic system: 
it 
R2 + 2C + 4 CAMP + R~cAMP,  + 2C 
Scheme 1 Kl 
where Kl is the dissociation constant for the binding of CAMP 
(or a derivative) to free regulatory subunits and K, for the 
binding between regulatory and catalytic subunits. It is 
assumed that activation is only effected by the release of free 
catalytic subunits, i. e. neither holoenzyme nor ternary com- 
plex [R, (cAMP),C,, n = 1 -41 possess detectable activity. For 
O + / ’  ’ I % 
o lo7 165 163 
[analog], M 
Fig. 3. Antagonistic activity qf  (R,)-CAMPS (9) and (RJ- 
cAMPNJCH,),  (0) for  mammalian kinuse type I .  0.1 pM cAMP was 
incubated in the presence of various concentrations of the derivatives. 
The kinase activity in the presence of 0.1 pM cAMP is set at 100% 
CAMPCI+ 3 ,  since the affinity for the holoenzyme was esti- 
mated to be 1000-fold lower than for free regulatory subunits 
[30]. In this way cAMP strongly shifts the binding equilibrium 
of the subunits to dissociation. However, for (RJ-CAMPS the 
apparent difference in binding affinity is smaller than for 
CAMP, in fact almost no difference is observed when binding 
without ATP (mainly free regulatory subunits) or with ATP 
(less free regulatory subunits and more holoenzyme) is moni- 
tored (Table 1). Thus CI is close to 1, implying that binding of 
(R,)cAMP will not induce holoenzyme dissociation. In short, CI 
is the factor that determines the maximal activation level and 
the difference between the binding affinities measured in the 
absence of ATP and in the presence of ATP. 
Antagonism 
Since (R,)-CAMPS and (RJ-cAMPN(CH,), showed re- 
duced agonistic activity, even at  concentrations which saturate 
the binding sites, we examined whether these compounds 
replace bound cAMP and thus inhibit a CAMP-induced 
stimulation of kinase activity. As shown in Fig. 3, (RJ -  
CAMPS antagonized the stimulation by 0.1 pM CAMP, while 
(R,)-cAMPN(CH,), showed no significant effect, which may 
have been caused by the extremely low affinity or by its partial 
agonistic activity (Fig. 2). According to the equation: 
Ka 
[CAMP] + K, Ki =I5,  
the Ki value for (R,)-CAMPS may be calcuAated from the 
concentration of (&)-CAMPS that inhibits 50/0 of the kinase 
activity (Z50 = 16 pM) using the K, for cAMP (0.034 pM) and 
the cAMP concentration (0.1 pM). The obtained Ki value of 
12 pM may then be related to the K, of CAMP, yielding a 6AG 
value of 14.8 kJ mol-’ which agrees with the value that was 
obtained from binding data : 15.2 kJ mol- for the ‘stable’ sites 
(B or 1) and 15.9 kJ mol-I for the ‘labile’ sites. The observed 
antagonistic behavior of (R,)-CAMPS was not caused by 
competition of this compound for the ATP binding site, since a 
higher cAMP concentration (1.0 pM) could overcome the 
inhibition by 100 pM (RJ-CAMPS: the inhibition decreased 
from 82 to 15 ?{. Furthermore, (R,)-CAMPS apparently is a 
competitive antagonist of cAMP (data not shown). 
Other CAMP-dependent protein kinases 
Table 2 summarizes the results from activation measure- 
ments with the four analogs modified in the exocyclic oxygen 
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Table 2. Properties of derivatives of c A M P  modified in the exocyclic 
oxygen atoms for  three types of CAMP-dependmt protein kinases 
Property Analog Value for  protein kinase 
____ 




CAMP 0.034 0 4  0.15 
(SJ-CAMPS 1.1 1.8 1.9 
= 11 3 
(S,)-cAMPN(CH,), 2.5 7.0 3.2 
(R,)-cAMPS - - 
(R,)-cAMPN(CH,), 2 200 -a  - 
Maximal (relative) 
activation 
CAMP 1.0 1.0 1.0 
(S,)-cAMPS 1.0 0.85 1.0 
(RJ-CAMPS < 0.03< 0.03 0.52 
(S,)-cAMPN(CHS), 0.75 1 .0 1.0 
(R,)-cAMPN(CH,), 2 0.4 < 0.03 -‘ 
Antagonism, PM 
K, 
(R,)-CAMPS 12.5 4.5 - b  
(R,)-cAMPN(CH,), - % 80 - c 
a Not determined because of inactivity of the derivative. 
No antagonism was observed, probably ;is a result of the partial 
‘ N o  (ant)agonism was observed, probably as a result of extremely 
agonistic potency of the compounds. 
low affinity of the derivative [3]. 
atoms using three kinases : mammalian type 1 and type I1 and 
from Dictyostelium discoideum. Obviously the mammalian 
types are closely related with respect to the agonistic and 
antagonistic effects which are induced by the derivatives. For 
the kinase from D. discoideum three of the derivatives are full 
agonists while only (R,)-CAMPS shows partial agonism; for 
this enzyme no useful antagonist was found within these four 
derivatives. 
DISCUSSION 
CAMP-dependent protein kinases have been extensively 
studied using derivatives of CAMP. Recently evidence has been 
accumulating that the two types of cAMP binding sites differ 
in kinetic properties [S] and specificity for certain derivatives 
[6 -121. The use of these site-specific analogs led to the 
proposal that both CAMP binding sites play a role in activation 
of the mammalian kinase [lo-121. Using a limited set of 
derivatives it was possible to obtain information about the 
interactions between cAMP and the ‘stable’ (B or 1) binding 
site [16]. In addition, a derivative modified in one of the 
exocyclic oxygen atoms on phosphorus, (R,)-ceMPS, was 
observoed to activate the kinase only partially : 20 k for type I 
and 5 / 0  for type I1 [16,17]. As is shown in tohis study these 
values are too high, since no detectable ( < 3 k )  stimulation 
was found using a highly purified preparation of (R,)-CAMPS. 
Also previously reported K, and K, values for (SJ-cAMPN- 
(CH,), proved to be too high: this compound activates and 
binds at lower concentrations than was observed with an 
impure preparation. The 6AG values are now about 11 
-12kJ mol-’ (Table 1)instead of 19 - 23 kJ mol-I [15]. Also 
Fig. 4. Formation of a trigonal bipyrarnidby endo attack ofufunctional 
group ( E l  of the regulatory subunit on phosphorus of  CAMP.  Endo 
attack on phosphorus renders (SJ-CAMPS (equatorial S after attack) 
as the preferential ligand when compared to (RJ-CAMPS (see [32]). 
Ad = adenine 
for the kinase from Dictyostelium discoideum a too high 6AG 
value for binding of (S,)-cAMPN(CH,), was obtained : 
17.5 kJ mol-l [3], while the purified preparation yielded 
8.0 kJ mol-l (data not shown). Based on these incorrect data 
for (SJ-cAMPN(CH,), an activation mechanism has been 
proposed requiring the negatively charged equatorial oxygen 
atom on phosphorus, However, the present work in which this 
uncharged compound is shown to be a much better ligand and 
activator of the type I kinase than reported before, suggests a 
clearly different interaction. Two possibilities are (a) polar 
interactions, such as hydrogen bonds or dipole interaction, 
and (b) a covalent bond with the binding site yielding a 
pentacovalent phosphorus atom. The formation of such a 
bond between cAMP and its receptor proteins has been 
suggested before [31]. Based on quantum chemical calcula- 
tions it was proposed that the cyclophosphate ring should be in 
diequatorial position, after nucleophile attack of an amino 
acid side chain in the binding site (Fig. 4). If one of the 
exocyclic oxygen atoms is replaced by a sulphur, the derivative 
with sulphur in equatorial position after endo attack of the 
enzyme [(SJ-CAMPS], should be energetically favored over 
the other isomer [32] ; as a consequence the S ,  isomer should be 
a better ligand and activator. Such calculations have not yet 
been performed for the phosphodimethylamidates, but it 
would be interesting to know whether the theoretical predic- 
tions in the case of endo attack fit the experimental data. 
As argued before, the absence of coupling between bind- 
ing and activation results in identical binding affinities in 
the presence and absence of ATP (Scheme 1). Of the 16 
derivatives tested, this was only found for, the binding of (RJ -  
CAMPS and of (RJ-cAMPN(CH,), to a minor extent, to both 
sites of kinase typeI. This implies that dissociation of 
holoenzyme coincides with the same change in binding of 
cAMP to both sites. It follows that the cyclophosphate region 
of cAMP in both binding sites is involved in activation of 
protein kinase type I and probably also the other types. This 
conclusion is in agreement with earlier reports [I0 - 121. 
According to Scheme 1, the coupling factor a is the link 
between binding of a CAMP derivative and subsequent 
activation of the enzyme. However, a given value of a may still 
effect activation levels between 0% and 100% depending on 
the enzyme concentration in relation to the binding affinity 
between the regulatory and the catalytic subunits. This may be 
easily understood from two extreme situations : (a) when a = 1 
and the enzyme concentration is much smaller than the 
dissociation constant (K,) for binding between the subunits, 
the kinase will be fully activated as a result of spontaneous 
dissociation; (b) when M = 100 and the enzyme concentration is 
much larger than 100 times the dissociation constant (a&) for 
the subunits, there will be no activation upon addition of the 
cyclic nucleotide. 
For the three investigated kinases similar relative activities 
of the R, and S,  isomers were observed: (S,)-CAMPS stimu- 
lates at lower concentrations than (R,)-CAMPS (which is only 
partially agonistic for the mammalian kinases and inactive for 
the D. cfiscoideum kinase). However, the levels of maximal 
activation by these compounds differ in these three kinases. 
According to the reasoning above, this does not necessarily 
imply that the activation mechanisms are different. More 
likely, the differences may be accounted for by different K2 
values (Scheme 1) and concentrations of the kinases. Thus, our 
data suggest a similar mechanism of activation for the three 
CAMP-dependent kinases. 
Summarizing, we have shown that cAMP is bound simi- 
larly to both types of binding sites of the protein kinase type I 
and subsequently induces activation of the enzyme via inter- 
action of the cyclophosphate regions of the cAMP molecules in 
the two distinct binding sites with a functional group of the 
regulatory subunit. The formation of these bonds causes a 
conformational change, which should lead to a decreased 
affinity between catalytic and regulatory subunits and thus 
formation of free, active catalytic subunits. 
The antagonistic activity of (R,)-CAMPS opens the way to 
investigation of the functioning of cAMP and CAMP-depen- 
dent protein kinases in oivo. Recently, this compound was 
indeed reported to antagonize glycogenolysis in isolated 
hepatocytes [33]. 
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